Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Biocept Inc's Business Segments
Biocept Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 1
Regions Reported
-
Biocept Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- Commercial Revenues91.2%
- Development Services Revenues6.3%
- Kits and B C T2.5%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Commercial Revenues | $ 1 | 91.2% |
| Development Services Revenues | $ 0 | 6.3% |
| Kits and B C T | $ 0 | 2.5% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Biocept Inc
Biocept Inc is a publicly-traded molecular diagnostics company based in San Diego, California, which specializes in developing liquid biopsy tests to improve the detection and monitoring of various types of cancer.
The company was founded in 1997 and went public in 2014 on the NASDAQ stock exchange under the symbol "BIOC". Since then, Biocept has become a trusted leader in the field of liquid biopsy testing, allowing physicians to analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other cancer biomarkers in the bloodstream. This approach enables doctors to make more informed decisions about cancer diagnoses, treatment plans, and monitoring.
Biocept's proprietary technology platform is called Target Selector, which is designed to capture and analyze rare cells and fragments of cancer DNA circulating in patients' blood. The company's liquid biopsy tests are used to detect, diagnose, and monitor various types of cancer, including lung, breast, colorectal, gastric, prostate, and melanoma.
In addition to its liquid biopsy tests, Biocept also offers a variety of other biomarker assays, including tests for HER2, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and more. These assays help doctors to guide targeted cancer therapies and monitor patients' responses to treatment.
Biocept has partnerships with major healthcare providers worldwide, including Quest Diagnostics and the University of Texas MD Anderson Cancer Center. The company also works closely with pharmaceutical companies to develop companion diagnostic tests for their cancer drugs.
Overall, Biocept is committed to advancing the diagnosis and treatment of cancer through innovative liquid biopsy testing, cutting-edge technology, and strategic partnerships with healthcare providers and pharmaceutical companies. The company's mission is to improve patient outcomes and enhance the quality of life for those affected by cancer.
The company was founded in 1997 and went public in 2014 on the NASDAQ stock exchange under the symbol "BIOC". Since then, Biocept has become a trusted leader in the field of liquid biopsy testing, allowing physicians to analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other cancer biomarkers in the bloodstream. This approach enables doctors to make more informed decisions about cancer diagnoses, treatment plans, and monitoring.
Biocept's proprietary technology platform is called Target Selector, which is designed to capture and analyze rare cells and fragments of cancer DNA circulating in patients' blood. The company's liquid biopsy tests are used to detect, diagnose, and monitor various types of cancer, including lung, breast, colorectal, gastric, prostate, and melanoma.
In addition to its liquid biopsy tests, Biocept also offers a variety of other biomarker assays, including tests for HER2, estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and more. These assays help doctors to guide targeted cancer therapies and monitor patients' responses to treatment.
Biocept has partnerships with major healthcare providers worldwide, including Quest Diagnostics and the University of Texas MD Anderson Cancer Center. The company also works closely with pharmaceutical companies to develop companion diagnostic tests for their cancer drugs.
Overall, Biocept is committed to advancing the diagnosis and treatment of cancer through innovative liquid biopsy testing, cutting-edge technology, and strategic partnerships with healthcare providers and pharmaceutical companies. The company's mission is to improve patient outcomes and enhance the quality of life for those affected by cancer.
Biocept Inc. is a prominent molecular diagnostics company focused on enhancing clinical decision-making through advanced diagnostic solutions aimed specifically at cancer care. The company operates through several comprehensive segments, each featuring a variety of innovative products and services designed to meet the needs of healthcare providers and their patients.
Segments:
Biocept Inc. consists of two primary segments, each tailored to address different aspects of cancer diagnostics:
1. Commercial Lab Services:
This segment encompasses an extensive array of molecular testing services aimed at providing actionable insights for physicians, hospitals, and adjacent healthcare providers. The key offerings include:
- Liquid Biopsy Tests: Non-invasive tests using blood samples to detect cancer variants. This includes tests focused on certain types of cancers such as lung, breast, prostate, and more, allowing for early detection and continuous monitoring of the disease.
- Consultative Support: Alongside the testing, Biocept Inc. offers guidance and expertise to help clinicians interpret the results, ensuring optimal treatment pathways for their patients.
2. Targeted Oncology:
In this segment, Biocept Inc. focuses on individualized patient care through genetic analysis tailored for oncology. The services include:
- Genetic Profiling Services: Identifying the genetic mutations and alterations within a patient’s tumor. These insights are crucial for determining targeted therapies that are most likely to be effective based on the specific genetic profile.
- Monitoring Disease Progression: Using molecular diagnostics to track how a cancer is responding to treatment over time, thus helping physicians adjust therapy as needed for better patient outcomes.
Products:
Biocept Inc. offers an array of innovative products primarily centered around liquid biopsy techniques. These products facilitate non-invasive cancer diagnostics and enable a clearer understanding of tumor biology:
1. Target Selector:
- This sophisticated liquid biopsy platform is designed to detect and analyze circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) found in blood samples. The Target Selector allows oncologists to monitor the effectiveness of treatment strategies and adjust them based on real-time insights into tumor dynamics.
2. Next-Generation Sequencing (NGS):
- Biocept provides an advanced NGS platform that encompasses a full spectrum of genetic tests. The flagship product, the OncoPanel, is capable of detecting mutations across 22 cancer-related genes, offering a deep insight into the tumor’s genetic landscape. This information is essential for developing tailored treatment plans for individual patients.
3. Circulating Tumor Cell (CTC) Analysis:
- Biocept’s CTC analysis product line focuses on isolating CTCs from peripheral blood. These analyses deliver critical intelligence on tumor behavior, including genetic mutation status, treatment resistance patterns, and insights into the heterogeneous nature of tumors, which can inform treatment decisions.
Services:
Biocept Inc. extends its offerings through several key services underlining its commitment to enhancing molecular diagnostics and improving patient care:
1. Liquid Biopsy Testing:
- The company provides robust liquid biopsy testing services that enable quick detection of cancer-related genetic mutations without the need for invasive tissue sampling. This method is ideal for patients who face prohibitive risks with traditional biopsies.
2. Comprehensive Tumor Profiling:
- Utilizing next-generation sequencing, Biocepts comprehensive tumor profiling service conducts an in-depth analysis of the tumor’s genetic makeup, revealing crucial data on mutations that drive cancer progression. This helps in framing personalized treatment plans that are targeted and effective.
3. Circulating Tumor Cell (CTC) Analysis:
- Biocept’s CTC analysis services further enhance cancer diagnostics by enabling the examination of CTCs from blood samples to better understand the cancers behavior, monitor treatment response, and assess the potential for metastatic spread.
Conclusion:
Overall, Biocept Inc. combines state-of-the-art technologies and a focus on molecular diagnostics to offer a unique and valuable portfolio of products and services. This cutting-edge approach not only aids in the timely diagnosis of cancers but also provides critical information that supports targeted therapies and personalized cancer treatments, ultimately enhancing patient care and outcomes. The company’s commitment to innovation and clinical utility positions it as a leader in the evolving landscape of cancer diagnostics.
Segments:
Biocept Inc. consists of two primary segments, each tailored to address different aspects of cancer diagnostics:
1. Commercial Lab Services:
This segment encompasses an extensive array of molecular testing services aimed at providing actionable insights for physicians, hospitals, and adjacent healthcare providers. The key offerings include:
- Liquid Biopsy Tests: Non-invasive tests using blood samples to detect cancer variants. This includes tests focused on certain types of cancers such as lung, breast, prostate, and more, allowing for early detection and continuous monitoring of the disease.
- Consultative Support: Alongside the testing, Biocept Inc. offers guidance and expertise to help clinicians interpret the results, ensuring optimal treatment pathways for their patients.
2. Targeted Oncology:
In this segment, Biocept Inc. focuses on individualized patient care through genetic analysis tailored for oncology. The services include:
- Genetic Profiling Services: Identifying the genetic mutations and alterations within a patient’s tumor. These insights are crucial for determining targeted therapies that are most likely to be effective based on the specific genetic profile.
- Monitoring Disease Progression: Using molecular diagnostics to track how a cancer is responding to treatment over time, thus helping physicians adjust therapy as needed for better patient outcomes.
Products:
Biocept Inc. offers an array of innovative products primarily centered around liquid biopsy techniques. These products facilitate non-invasive cancer diagnostics and enable a clearer understanding of tumor biology:
1. Target Selector:
- This sophisticated liquid biopsy platform is designed to detect and analyze circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) found in blood samples. The Target Selector allows oncologists to monitor the effectiveness of treatment strategies and adjust them based on real-time insights into tumor dynamics.
2. Next-Generation Sequencing (NGS):
- Biocept provides an advanced NGS platform that encompasses a full spectrum of genetic tests. The flagship product, the OncoPanel, is capable of detecting mutations across 22 cancer-related genes, offering a deep insight into the tumor’s genetic landscape. This information is essential for developing tailored treatment plans for individual patients.
3. Circulating Tumor Cell (CTC) Analysis:
- Biocept’s CTC analysis product line focuses on isolating CTCs from peripheral blood. These analyses deliver critical intelligence on tumor behavior, including genetic mutation status, treatment resistance patterns, and insights into the heterogeneous nature of tumors, which can inform treatment decisions.
Services:
Biocept Inc. extends its offerings through several key services underlining its commitment to enhancing molecular diagnostics and improving patient care:
1. Liquid Biopsy Testing:
- The company provides robust liquid biopsy testing services that enable quick detection of cancer-related genetic mutations without the need for invasive tissue sampling. This method is ideal for patients who face prohibitive risks with traditional biopsies.
2. Comprehensive Tumor Profiling:
- Utilizing next-generation sequencing, Biocepts comprehensive tumor profiling service conducts an in-depth analysis of the tumor’s genetic makeup, revealing crucial data on mutations that drive cancer progression. This helps in framing personalized treatment plans that are targeted and effective.
3. Circulating Tumor Cell (CTC) Analysis:
- Biocept’s CTC analysis services further enhance cancer diagnostics by enabling the examination of CTCs from blood samples to better understand the cancers behavior, monitor treatment response, and assess the potential for metastatic spread.
Conclusion:
Overall, Biocept Inc. combines state-of-the-art technologies and a focus on molecular diagnostics to offer a unique and valuable portfolio of products and services. This cutting-edge approach not only aids in the timely diagnosis of cancers but also provides critical information that supports targeted therapies and personalized cancer treatments, ultimately enhancing patient care and outcomes. The company’s commitment to innovation and clinical utility positions it as a leader in the evolving landscape of cancer diagnostics.